Comparing aspirin and warfarin after mitral valve repair surgery

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the safety and effectiveness of early administration of aspirin versus warfarin in patients who have undergone mitral valve repair surgery. Participants are randomly assigned to receive either aspirin or warfarin starting on the second day post-surgery, with the aim of assessing clinical outcomes and the incidence of thromboembolic and bleeding complications within three months. Follow-up visits are scheduled at 1, 4, 8, and 12 weeks after the surgery to monitor patient progress and medication effects.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Individuals aged 18 years and above, but not exceeding 85 years;
* Patients who have successfully undergone mitral valve plasty with implantation of a mitral annuloplasty ring, with the option to undergo concurrent tricuspid valve plasty, atrial septal defect repair, or myxoma resection;
* Patients with preoperative electrocardiogram (ECG) showing sinus rhythm;
* Alternatively, patients with preoperative ECG showing atrial fibrillation (AF) rhythm, but who are male with a CHA2DS2-VASc-60 score of 0 or female with a score of 1; for patients with a CHA2DS2-VASc-60 score exceeding the aforementioned values but who have successfully converted to sinus rhythm following concurrent radiofrequency catheter ablation for AF;
* Patients who voluntarily participate in this study, have signed a written informed consent form, and are willing to comply with follow-up procedures.

Exclusion Criteria:

* Patients with contraindications to any of the following medications: heparin, warfarin, or aspirin;
* Patients who have undergone artificial valve replacement at other valve positions;
* Patients with a high risk of bleeding (including active bleeding, platelet count \<50×10\^9/L, hemoglobin \<8.0 g/dL, history of cerebral hemorrhage, active peptic ulcer, or history of gastrointestinal bleeding within the last 3 months);
* Patients with acute coronary syndrome within the last month;
* Patients with symptomatic stroke within the last 3 months;
* Patients with renal insufficiency and a creatinine clearance rate \<30 mL/min; Dialysis patients;
* Patients with moderate or severe hepatic impairment or liver disease with coagulation dysfunction: Child-Pugh score greater than B or bilirubin greater than or equal to 2 times the upper limit of normal (ULN) as defined by the center, and alanine aminotransferase (ALT), aspartate aminotransferase (AST), or serum alkaline phosphatase (ALP) levels greater than or equal to 3 times the ULN as defined by the center;
* Patients with active malignant tumors;
* Patients who are planned to undergo surgical intervention or treatment (including endoscopy) during the trial period that requires discontinuation of anticoagulants;
* Pregnant or lactating women, or fertile individuals unwilling or unable to use effective contraceptives;
* Patients who have participated in any drug clinical trial within the last 6 months prior to screening;
* Patients who refuse to undergo follow-up;
* Patients deemed unsuitable for participation in this study by the investigator.

Where it's running

• Guangdong Provincial People's Hospital
  Guangzhou, Guangdong, China Recruiting

Study contacts

• Study coordinator: Huanlei Huang Phd
• Email: hhuanlei@hotmail.com
• Phone: 765-714-9765

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• AI-generated interactive video instructions for mitral valve repair

  This trial tests whether an AI-generated, interactive peri-operative video program can reduce unplanned hospital visits and readmissions for adults having elective, isolated mitral valve repair.

  Recruiting Cedars-Sinai Medical Center · Los Angeles, California · NCT07036926

• Active safety and performance monitoring of a biodegradable PFO closure device and a transcatheter mitral valve repair system

  This study tracks how well a biodegradable PFO closure device and a transcatheter mitral valve repair system work and stay safe when used in routine care.

  Recruiting at 3 sites Shanghai Jiao Tong University School of Medicine · Lanzhou, Gansu and 10 other locations · NCT07848152

• Edge-to-edge mitral valve repair for ATTR-CM with mitral regurgitation

  This trial tests whether adding transcatheter edge-to-edge mitral valve repair helps patients with ATTR-associated cardiomyopathy and significant mitral regurgitation compared with standard medical therapy alone.

  Recruiting at 8 sites Medical University of Vienna · Graz and 9 other locations · NCT06075823

• Left atrial appendage closure with AtriLASH Seralene suture during cardiac surgery for atrial fibrillation

  This trial tests whether closing the left atrial appendage with the AtriLASH Seralene hemostatic suture during cardiac surgery can reduce stroke risk in adults with atrial fibrillation.

  Recruiting Institute of Cardiovascular Diseases, Vojvodina · Kamenitz, Vojvodina · NCT07360899

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.